title: Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
abstract: The development of subunit vaccines requires the use of adjuvants that act by stimulating components of the innate immune response. Immune-stimulating complexes (ISCOMS) containing the saponin adjuvant Quil A are potential vaccine vectors that induce a wide range of Ag-specific responses in vivo encompassing both humoral and CD4 and CD8 cell-mediated immune responses. ISCOMS are active by both parenteral and mucosal routes, but the basis for their adjuvant properties is unknown. Here we have investigated the ability of ISCOMS to recruit and activate innate immune responses as measured in peritoneal exudate cells. The i.p. injection of ISCOMS induced intense local inflammation, with early recruitment of neutrophils and mast cells followed by macrophages, dendritic cells, and lymphocytes. Many of the recruited cells had phenotypic evidence of activation and secreted a number of inflammatory mediators, including nitric oxide, reactive oxygen intermediates, IL-1, IL-6, IL-12, and IFN-gamma. Of the factors that we investigated further only IL-12 appeared to be essential for the immunogenicity of ISCOMS, as IL-6- and inducible nitric oxide synthase knockout (KO) mice developed normal immune responses to OVA in ISCOMS, whereas these responses were markedly reduced in IL-12KO mice. The recruitment of peritoneal exudate cells following an injection of ISCOMS was impaired in IL-12KO mice, indicating a role for IL-12 in establishing the proinflammatory cascade. Thus, ISCOMS prime Ag-specific immune responses at least in part by activating IL-12-dependent aspects of the innate immune system.
authors.affiliation: Department of Immunology, University of Glasgow, Western Infirmary, United Kingdom.
authors.forename: R E
authors.initials: RE
authors.lastname: Smith
authors.forename: A M
authors.initials: AM
authors.lastname: Donachie
authors.forename: D
authors.initials: D
authors.lastname: Grdic
authors.forename: N
authors.initials: N
authors.lastname: Lycke
authors.forename: A M
authors.initials: AM
authors.lastname: Mowat
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D001202:Ascitic Fluid / Q000276:immunology / Q000473:pathology; D002465:Cell Movement / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D000939:Epitopes / Q000276:immunology; D005260:Female; D016882:ISCOMs / Q000008:administration & dosage* / Q000276:immunology*; D007113:Immunity, Innate / Q000235:genetics; D016130:Immunophenotyping; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007274:Injections, Intraperitoneal; D018664:Interleukin-12 / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009569:Nitric Oxide / Q000096:biosynthesis; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D062605:Quillaja Saponins; D017382:Reactive Oxygen Species / Q000378:metabolism; D012503:Saponins / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D000939:Epitopes; D016882:ISCOMs; D062605:Quillaja Saponins; D017382:Reactive Oxygen Species; D012503:Saponins; D018664:Interleukin-12; D009569:Nitric Oxide; C046386:Quil A; D010047:Ovalbumin